SEPN Septerna, Inc.
Septerna, Inc. (SEPN) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.52 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.5% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Septerna, Inc.
Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif.
Sector
Healthcare
Industry
Biotechnology